Prehospital transfusion of allogeneic blood products
- PMID: 38390984
- DOI: 10.1097/ACO.0000000000001353
Prehospital transfusion of allogeneic blood products
Abstract
Purpose of review: The purpose of this article is to provide a structural and practical analysis of the currently available data concerning prehospital transfusion of allogeneic blood products in cases of trauma and severe bleeding.
Recent findings: Prehospital transfusion of allogeneic blood products is a very early intervention, which may offer the potential to improve outcome, but that also comes with challenges including resource allocation, blood product storage, logistics, patient selection, legal and ethical considerations, adverse effects, and costs. Potential benefits including improved stability and reduction in coagulopathy and blood loss have not yet been clearly demonstrated.
Summary: The questionable efficacy and challenges in clinical practice may outweigh the potential benefits of prehospital allogeneic transfusion.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Rehn M, Weaver A, Brohi K, et al. Effect of prehospital red blood cell transfusion on mortality and time of death in civilian trauma patients. Shock 2019; 51:284–288.
-
- Shackelford SA, Del Junco DJ, Powell-Dunford N, et al. Association of prehospital blood product transfusion during medical evacuation of combat casualties in Afghanistan with acute and 30-day survival. JAMA 2017; 318:1581–1591.
-
- Holcomb JB, Donathan DP, Cotton BA, et al. Prehospital transfusion of plasma and red blood cells in trauma patients. Prehosp Emerg Care 2015; 19:1–9.
-
- Sperry JL, Guyette FX, Brown JB, et al. PAMPer Study Group. Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock. N Engl J Med 2018; 379:315–326.
-
- Crombie N, Doughty HA, Bishop JRB, et al. RePHILL collaborative group. Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol 2022; 9:e250–e261.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
